Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

ProteinS (1)


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 10 records in total 14
    records per page




    A BIBLIOMETRIC ANALYSIS OF RHEUMATOLOGY AND COVID-19 MESHD RESEARCHES

    Authors: Ozge Pasin; Tugce Pasin

    doi:10.1101/2021.03.31.21254695 Date: 2021-04-06 Source: medRxiv

    Objectives: COVID-19 MESHD has had a substantial impact on rheumatology. This study provides a general overview of studies on rheumatology and COVID-19 MESHD. Methods: Data were taken from the Web of Science (WoS) website. Analysis and network visualization mapping processes were carried out using VOSviewer. A total of 234 publications were analyzed, and the correlations between citation numbers and reference counts, usage counts and page numbers were analyzed with Spearman correlation coefficients. Results: The average number of citations per item was 6.03. The studies were cited 1,411 times in total, and 1,121 times without self-citations. The countries with the highest number of publications on rheumatology and COVID-19 MESHD were the USA and England; the countries with the highest number of citations were Italy and the USA, and Jinoos Yazdany was the most cited author. The Annals of the Rheumatic Diseases MESHD was the most cited journal, whereas the highest number of articles on rheumatology and COVID-19 MESHD were published in Arthritis MESHD and Rheumatology. Conclusions: Bibliometric analysis of rheumatology and COVID-19 MESHD can be useful to future studies because it provides a general perspective on the studies. This study provides an insight into the development of publications on rheumatology during the COVID-19 pandemic MESHD.

    UBXN3B Restricts Viral Pathogenesis by Maintaining Hematopoietic Homeostasis MESHD

    Authors: PENGHUA WANG; Tingting Geng; Duomeng Yang; Tao Lin; Andrew Harrison; Laura Haynes; Blake Torrance; Binsheng Wang; Anthony T. Vella; Gong Cheng; Erol Fikrig; Long Yang

    doi:10.1101/2021.03.04.433919 Date: 2021-03-04 Source: bioRxiv

    Hematopoiesis is finely regulated to enable timely production of the right number and type of mature immune cells to maintain tissue homeostasis. Dysregulated hematopoiesis MESHD may compromise antiviral immunity and/or exacerbate immunopathogenesis. Herein, we report an essential and new role of ubiquitin X domain containing gene 3B (UBXN3B) in balancing myelopoiesis MESHD and lymphopoiesis. Ubxn3b deficiency (Ubxn3b-/-) results in a remarkable increase in myeloid cells and neutrophil-to-lymphocyte ratio, along with a reduction in lymphocytes in steady-state mice. This dysregulation is exacerbated during viral infection MESHD and renders mice highly vulnerable to severe lung pathology induced by severe acute respiratory syndrome coronavirus 2 MESHD and arthritis MESHD by arthritogenic alphaviruses. Ubxn3b-/- mice present normal type I IFNs, higher viral loads and inflammatory mediators, lower virus-specific immunoglobulin G and slower resolution of disease, when compared to Ubxn3b+/+ littermates. Mechanistically, Ubxn3b-/- mice have fewer multipotent progenitors and common lymphoid progenitors, but more common myeloid progenitors. In particular, the precursor and immature B cell numbers are dramatically decreased in the bone marrow of Ubxn3b-/- mice. These data demonstrate that UBXN3B signaling is essential for restricting viral infection MESHD and immunopathogenesis by maintaining hematopoietic homeostasis.

    Patient re-presents to the clinic with reactive arthritis MESHD in the right hip after covid-19 MESHD infection: A case report

    Authors: Kamyar Shokraee; Soroush Moradi; Tahereh Eftekhari; Rasoul Shajari; Maryam Masoumi

    doi:10.21203/rs.3.rs-230354/v1 Date: 2021-02-11 Source: ResearchSquare

    Background: SARS-COV-2, first reported in December 2019, usually presents with respiratory symptoms but can have various other manifestations and sequelae. One of the rare complications of COVID-19 MESHD infection is Reactive Arthritis MESHD. This complication is more likely to occur following sexually transmitted or gastrointestinal infection MESHD.Case presentation: Herein, we report a 58 years old woman hospitalized following COVID-19 MESHD infection and was discharged after a week. She consequently presented to the clinic ten days after her discharge, complaining of walking difficulties and radiating pain MESHD in her right hip. After ultrasound and MRI, she was diagnosed with reactive arthritis inflammation MESHD in the hip’s neck. Other known microorganisms responsible for reactive arthritis MESHD were ruled out before attributing it to the earlier COVID-19 MESHD infection. She reached remission after being treated using a combination of indomethacin and depot methyl-prednisolone for 14 days. Conclusion: To our knowledge, this is the first case of reactive arthritis MESHD caused by SARS-COV-2 in the hip. Further attention should be paid to symptoms occurring after an episode of infection with COVID-19 MESHD in order to expand our understanding of the disease and the symptoms with which it can manifest.

    Feasibility of Virtual Research on the Psychological Status and Group Exercises among Community-Dwelling Older Adults during the COVID-19 Pandemic MESHD

    Authors: Amirah Ibrahim; Mei Chan Chong; Selina Khoo; Li Ping Wong; Ivy Chung; Maw Pin Tan

    id:202102.0281/v1 Date: 2021-02-11 Source: Preprints.org

    Social isolation magnified by the restriction of movement order during the COVID-19 pandemic MESHD may lead to negative psychosocial MESHD health impact among community-dwelling older adults. We evaluated the feasibility of virtual research methods and virtual group exercises among individuals aged 60 years and over in Malaysia. Participants were recruited from the Promoting Independence in Seniors with Arthritis MESHD (PISA) pilot cohort through social media messages. A four-week course of virtual group exercise was offered. Anxiety MESHD and depression MESHD were assessed with the Hospital Anxiety and Depression MESHD Scale ( HADS MESHD) during the last attended follow-up of the cohort study (pre-pandemic), pre-intervention, and post-intervention. Exercise adherence was recorded using diary with daily entries and attendance to the virtual group exercise sessions were captured daily. The outcomes of interest were changes of anxiety MESHD and depression MESHD scores from baseline to pre-intervention (pandemic-related) and post-intervention (virtual exercise related). Forty-three individuals were recruited. A significant increase in anxiety MESHD scores from baseline to pre-intervention was observed. Comparisons using repeated-measures analysis of variance between those who attendance ≥14 and <14 group exercise sessions revealed no between-within subjects differences in depression MESHD scores. There was a 23% dropout rate in the post intervention survey and 60.5% of diaries were returned. This study demonstrated the feasibility of conducting research entirely virtually among older persons during the peak of global first wave of a pandemic. The pandemic has led to increased anxiety MESHD among community-dwelling older adults.

    Prophylactic or therapeutic administration of Holarrhena floribunda hydro ethanol extract suppresses Complete Freund’s Adjuvant-induced arthritis MESHD in Sprague-Dawley rats    

    Authors: Stephen Antwi; Daniel Oduro-Mensah; David Darko Obiri; Clara Lewis; Ebenezer Oduro-Mensah; Augustine Ocloo; Laud Okine

    doi:10.21203/rs.3.rs-126064/v1 Date: 2020-12-10 Source: ResearchSquare

    Ethnopharmacological relevance In Ghanaian folk medicine, Holarrhena floribunda has anecdotal use for the treatment of inflammatory conditions. A hydro ethanol extract of the stem bark has previously been shown to be effective in the management of acute infl ammation and MESHD anap hylaxis in MESHDrodents.Aim of the study This study was aimed at evaluating the usefulness of H. floribunda stem bark hydro ethanol extract (HFE) for the management of chronic infl ammation in MESHDa murine model.Materials and Methods Anti-arthritic effect of the extract was evaluated using Complete Freund’s Adjuvant-induced arth ritis in MESHDmale Sprague-Dawley rats. Using both prophylactic and therapeutic treatment models, parameters assessed included oede ma, se MESHDrology of inflammatory response, radiology, bone tissue histology and haematology. Data were analysed by ANOVA followed by Tukey’s multiple comparisons post hoc test.Results HFE at 50–500 mg/kg dose-dependently [P ≥ 0.0354 (prophylactic) and P ≥ 0.0001 (therapeutic)] inhibited swelling of the injected paw upon prophylactic [≤ 81.26 % (P < 0.0001)] or therapeutic [≤ 67.92 % (P < 0.01)] administration — and prevented spread of arth ritis to MESHDthe contralateral paw. Inflammation alleviation activity of HFE was further demonstrated by decrease in arth ritis sco MESHDre, radiologic score and erythrocyte sedimentation rate. HFE at all doses significantly reduced serum IL-1α (P < 0.0197), and 500 mg/kg HFE reduced serum IL-6 (P = 0.0032). In contrast, serum concentrations of IL-10, protein kinase A and cyclic adenosine monophosphate were enhanced (P ≤ 0.0436). HFE consistently showed better prophylactic activity than when administered therapeutically.Conclusions The data demonstrate that HFE suppresses CFA-induced arth ritis and MESHD modulates regulators of infl ammation; in MESHDcluding IL-1α, -6 and -10 which also play mediatory roles in several immune response pathways. These make HFE a strong candidate for development as an agent for management and modulation of infl ammation and MESHD the inflammatory response, including immune response-related adverse events such as seen in severe COVID-19 MESHD.  

    A novel multi-omics-based identification of symptoms, comorbid conditions, and possible long-term complications in COVID-19 MESHD

    Authors: Debmalya Barh; Sandeep Tiwari; Bruno Silva Andrade; Marianna E. Weener; Aristoteles Goes-Neto; Vasco Azevedo; Preetam Ghosh; Nirmal Kumar Ganguly

    doi:10.1101/2020.12.08.20245753 Date: 2020-12-09 Source: medRxiv

    Till date the comprehensive clinical pictures, comorbid conditions, and long-term complications of COVID-19 MESHD are not known. Recently using a multi-omics-based strategy, we have predicted the drugs for COVID-19 MESHD management with [~]70% accuracy. Here, using a similar multi-omics-based bioinformatics approach and three-ways of analysis, we identified the symptoms, comorbid conditions, and short, mid and possible long-term complications of COVID-19 MESHD with [~]90% precision. In our analysis (i) we identified 27 parent, 170 child, and 403 specific conditions associated with COVID-19 MESHD. (ii) Among the specific conditions, 36 are viral and 53 short-term, 62 short to mid to long-term, 194 mid to long-term, and 57 are congenital conditions. (iii) At a cut off "count of occurrence" of 4, we found [~] 90% of the enriched conditions are associated with COVID-19 MESHD. (iv) Except the dry cough MESHD and loss of taste, all other COVID-19 MESHD associated mild and severe symptoms are enriched. (v) Cardiovascular, pulmonary, metabolic, musculoskeletal MESHD, neuropsychiatric, kidney, liver, and immune system disorders MESHD are found as top comorbid conditions. (vi) Specific diseases such as myocardial infarction MESHD, hypertension MESHD, COPD MESHD, lung injury MESHD, diabetes MESHD, cirrhosis MESHD, mood disorders MESHD, dementia MESHD, macular degeneration MESHD, chronic kidney disease MESHD, lupus MESHD, arthritis MESHD etc. along with several other diseases MESHD are also enriched as top candidates. (vii) Interestingly, many cancers MESHD and congenital disorders MESHD associated with COVID-19 MESHD severity are also identified. (viii) Arthritis MESHD, dermatomyositis MESHD, glioma MESHD, diabetes MESHD, psychiatric disorder MESHD, cardiovascular diseases MESHD having bidirectional relationship with COVID-19 MESHD are also found as top ranked conditions. Based on the accuracy ([~]90%) of this analysis, long presence of SARS-CoV-2 RNA in human, and our previously proposed "genetic remittance" assumption, we hypothesize that all the identified comorbid conditions including the short-long-mid and mid-long non-communicable diseases (NCDs) could also be long-term consequences in COVID-19 MESHD survivors and warrants long-term observational studies.

    Performance of SARS-CoV-2 Serology tests: Are they good enough?

    Authors: Isabelle Piec; Emma English; Mary Anette Thomas; Samir Darvisevic; William Duncan Fraser; William Garry John

    doi:10.1101/2020.11.13.20229625 Date: 2020-11-16 Source: medRxiv

    Background In the emergency of the SARS-CoV-2 pandemic, great efforts were made to quickly provide serology testing to the medical community however, these methods have been introduced into clinical practice without the complete validation usually required by the regulatory organizations. Methods SARS-CoV-2 patient samples (n=43) were analysed alongside pre-pandemic control specimen (n=50), confirmed respiratory infections MESHD (n=50), inflammatory polyarthritis MESHD (n=22) and positive for thyroid stimulating immunoglobulin (n=30). Imprecision, diagnostic sensitivity and specificity and concordance were evaluated on IgG serologic assays from EuroImmun, Epitope Diagnostics (EDI), Abbott Diagnostics and DiaSorin and a rapid IgG/IgM test from Healgen. Results EDI and EuroImmun imprecision was 0.02-14.0% CV. Abbott and DiaSorin imprecision (CV) ranged from 5.2% - 8.1% and 8.2% - 9.6% respectively. Diagnostic sensitivity of the assays were 100% (CI: 80-100%) for Abbott, EDI and EuroImmun and 95% (CI: 73-100%) for DiaSorin at [≥]14 days post PCR. Only the Abbott assay had a diagnostic specificity of 100% (CI: 91-100%). EuroImmun cross-reacted in 3 non- SARS-CoV-2 respiratory infections MESHD and 2 controls. The DiaSorin displayed more false negative results and cross-reacted in six cases across all conditions tested. EDI had one cross-reactive sample. The Healgen rapid test showed excellent sensitivity and specificity. Overall, concordance of the assays ranged from 76.1% to 97.9%. Conclusions Serological tests for SARS-CoV-2 showed good analytical performance. The head-to-head analysis of samples revealed differences in results that may be linked to the use of nucleocapsid or spike proteins PROTEIN. The point of care device tested demonstrated adequate performance for antibody detection.

    The First Case of Reactive Arthritis Associated with SARS-CoV-2-Infection in A 4-Year Old Child

    Authors: Stephanie Gabriele Werner; Hans-Eckhard Langer

    doi:10.21203/rs.3.rs-106976/v1 Date: 2020-11-12 Source: ResearchSquare

    Background: The novel coronavirus SARS‐CoV‐2 MESHD (severe acute respiratory syndrome coronavirus 2 MESHD) and its associated disease COVID‐19 ( Corona Virus Disease MESHD 19) has become a worldwide pandemic since its first cases in December 2019 in Wuhan Province in China. In Germany the pandemic started in February 2020.Case presentation: A 4 year old boy was presented and suffered from pain MESHD in the right hip. Arthrosonography demonstrated a significant effusion in the involved joint. The extended history revealed a slight but long lasting cold before. Serological findings were inconspicuous except for positive ELISA (Enzyme-linked Immuno Sorbent Assay) - test for SARS-CoV-2. Conclusion: In conclusion we believe that we can report the first case of reactive arthritis MESHD associated with SARS-CoV-2 in children.

    Post nCoV-2 limping Child: Report of two cases and a rapid Review

    Authors: Reza Sinaei; Sara Pezeshki; Roya Sinaei; Reza Shiari; Mehrnoush Hassas Yeganeh; Saeedeh Parvaresh; Nasrin Bazargn

    doi:10.21203/rs.3.rs-59943/v1 Date: 2020-08-15 Source: ResearchSquare

    Background: Identification of the etiology of acute limping in children is challenging. Both benign and life- threatening disorders can present with limp. However, among atraumatic conditions MESHD, benign conditions including toxic synovitis MESHD and post infectious arthritis MESHD are the most common causes of this dilemma. Case Presentation: During the recent COVID-19 pandemic MESHD COVID-19 pandemic MESHD in Kerman, South East of Iran; two pediatric patients referred to the Rheumatology clinic with new onset gait disturbance MESHD. One 8 years old boy and the other 6 years old girl who presented with hip joint pain MESHD and limping. Both of them had joint effusion jackknife of mild respiratory symptoms and fever MESHD. Altogether, precise history taking and accurate physical examination, alongside radiological investigations and positive laboratory results for coronavirus infection MESHD emphasized the diagnosis of post Coronavirus arthritis MESHD.  They treated with rest and Non-Steroidal Anti-Inflammatory Drugs (NSAID) successfully, and fallowed at least for one month later.Conclusions: Here, we described the first report of post n-CoV-2 arthritis MESHD in the world in two Iranian pediatric patients, who presented with limp. Contrary to preliminary phantasms, this may indicate that the Corona virus has some rheumatogenic specifications.

    Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection MESHD in a large cohort of patients with chronic inflammatory arthritis MESHD

    Authors: Ennio Giulio Favalli; Serena Bugatti; Catherine Klersy; Martina Biggioggero; Silvia Rossi; Orazio De Lucia; Francesca Bobbio-Pallavicini; Antonella Murgo; Silvia Balduzzi; Roberto Caporali; Carlomaurizio Montecucco

    doi:10.21203/rs.3.rs-51667/v3 Date: 2020-07-31 Source: ResearchSquare

    Background: Prevalence and outcomes of Coronavirus Disease MESHD (COVID)-19 in relation to immunomodulatory medications are still unknown. The aim of the study is to investigate the impact of glucocorticoids and immunosuppressive agents on COVID-19 MESHD in a large cohort of patients with chronic immune-mediated inflammatory arthritis MESHD.Methods: The study was conducted in the arthritis MESHD outpatient clinic at two large Academic Hospitals in the COVID-19 MESHD most endemic area of Northern Italy (Lombardy). We circulated a cross-sectional survey exploring the prevalence of Severe Acute Respiratory Syndrome-Coronavirus-2 MESHD nasopharyngeal swab positivity and the occurrence of acute respiratory illness MESHD (fever and/or cough and/or dyspnea MESHD), administered face-to-face or by phone to consecutive patients from 25th February to 20th April 2020. COVID-19 MESHD cases were defined as confirmed or highly suspicious according to the World Health Organization criteria. The impact of medications on COVID-19 MESHD development was evaluated. Results: The study population included 2050 adults with chronic inflammatory arthritis MESHD receiving glucocorticoids, conventional-synthetic (cs), or targeted-synthetic/biological (ts/b) disease-modifying drugs (DMARDs). Laboratory-confirmed COVID-19 MESHD and highly suspicious infection were recorded in 1.1% and 1.4% of the population, respectively. Treatment with glucocorticoids was independently associated with increased risk of COVID-19 MESHD (adjusted OR [95% CI] ranging from 1.23 [1.04-1.44] to 3.20 [1.97-5.18] depending on the definition used). Conversely, patients treated with ts/bDMARDs were at reduced risk (adjusted OR ranging from 0.46 [0.18-1.21] to 0.47 [0.46-0.48]). No independent effects of csDMARDs, age, sex, and comorbidities were observed.Conclusions: During the COVID-19 MESHD outbreak, treatment with immunomodulatory medications appears safe. Conversely, glucocorticoids, even at low-dose, may confer increased risk of infection.Trial registration:  retrospectively registered

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.